Ovarian Cancer Vaccine Technology Patented in Europe
California-based Anixa Biosciences, Inc. announced that the European Patent Office has issued and published the first European patent for its novel ovarian cancer vaccine technology.
The patent is titled "Ovarian Cancer Vaccines," and the inventors are Drs. Vincent K. Tuohy, Suparna Mazumder, and Justin M. Johnson, all of Cleveland Clinic. This technology was developed at Cleveland Clinic, and Anixa is the worldwide licensee.
"The ovarian cancer vaccine targets a protein (the Extracellular Domain of the Anti-Mullerian Hormone Receptor 2, AMHR2-ED) that is expressed only in the ovaries and only in pre-menopausal women. After menopause, the target protein disappears and is only seen again when ovarian cancer cells arise. Our vaccine targets the AMHR2-ED and trains the immune system to destroy these cancer cells as they arise," commented Dr. Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute in a press release issued on March 12, 2021.
"We are looking forward to our continued alliance with Anixa Biosciences to develop this technology further."
Anixa is a publicly-traded biotechnology company developing several programs addressing cancer and infectious disease.